Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptose Bioscns (NQ: APTO )

0.4048 UNCHANGED
Streaming Delayed Price Updated: 3:56 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 675
Open 0.4048
Bid (Size) 0.3800 (2)
Ask (Size) 0.4046 (13)
Prev. Close 0.4048
Today's Range 0.4048 - 0.4048
52wk Range 0.3316 - 3.520
Shares Outstanding 93,653,662
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aptose Announces Results from Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-82.99%
-82.99%
1 Month
-16.54%
-16.54%
3 Month
-51.64%
-51.64%
6 Month
-73.01%
-73.01%
1 Year
-88.30%
-88.30%

More News

Read More
Hello Group, Zscaler And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
From Aptose Biosciences, Inc.
Via GlobeNewswire
Recap: Aptose Biosciences Q4 Earnings
Via Benzinga
Aptose Announces Adjournment of its Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024
Via InvestorPlace
Aptose Reports Results for the Second Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Receipt of Deficiency Notice from Nasdaq
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences's Earnings: A Preview
Via Benzinga
Aptose Announces Results from Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Aptose Biosciences, Inc.
Via GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024
Via InvestorPlace
Aptose Reports Results for the First Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023
Via InvestorPlace
Aptose Reports Results for the Fourth Quarter and Full Year 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For March 26, 2024
Via Benzinga
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
From Aptose Biosciences, Inc.
Via GlobeNewswire
Levi Strauss Layoffs 2024: What to Know About the Latest LEVI Job Cuts
Via InvestorPlace
Topics Economy Workforce
Exposures Economy Layoff
Why Is SU Group (SUGP) Stock Moving Today?
Via InvestorPlace
Topics Initial Public Offering
Exposures Securities Market
Why Is Aptose Biosciences (APTO) Stock Down Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.